Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IQV 
IQVIA Holdings Inc (IQV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: IQV (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
23 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $246.84
1 Year Target Price $246.84
| 14 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.99% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 35.84B USD | Price to earnings Ratio 28.95 | 1Y Target Price 246.84 |
Price to earnings Ratio 28.95 | 1Y Target Price 246.84 | ||
Volume (30-day avg) 23 | Beta 1.38 | 52 Weeks Range 134.65 - 225.00 | Updated Date 11/7/2025 |
52 Weeks Range 134.65 - 225.00 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 7.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When Before Market | Estimate 2.97 | Actual 3 |
Profitability
Profit Margin 8.07% | Operating Margin (TTM) 13.98% |
Management Effectiveness
Return on Assets (TTM) 5.07% | Return on Equity (TTM) 19.37% |
Valuation
Trailing PE 28.95 | Forward PE 15.6 | Enterprise Value 48249800000 | Price to Sales(TTM) 2.25 |
Enterprise Value 48249800000 | Price to Sales(TTM) 2.25 | ||
Enterprise Value to Revenue 3.07 | Enterprise Value to EBITDA 14.41 | Shares Outstanding 170300000 | Shares Floating 161774782 |
Shares Outstanding 170300000 | Shares Floating 161774782 | ||
Percent Insiders 1.05 | Percent Institutions 102.45 |
Upturn AI SWOT
IQVIA Holdings Inc
Company Overview
History and Background
IQVIA Holdings Inc. was formed in 2017 through the merger of IMS Health and Quintiles. IMS Health, founded in 1954, specialized in healthcare information and technology services. Quintiles, founded in 1982, focused on biopharmaceutical development and commercial outsourcing services. The merger created a comprehensive provider of biopharmaceutical development and commercial services.
Core Business Areas
- Technology & Analytics Solutions: Provides technology solutions, including software platforms, data analytics, and real-world evidence offerings, to improve clinical and commercial performance for healthcare clients.
- Research & Development Solutions: Offers clinical trial management, central laboratory services, and other research and development support to biopharmaceutical companies.
- Commercial Solutions: Provides commercial outsourcing services, including sales force deployment, marketing solutions, and market access strategies, to help clients commercialize their products effectively.
Leadership and Structure
Ari Bousbib is the Chairman and CEO. The organizational structure includes functional departments overseeing the core business areas, as well as corporate functions such as finance, legal, and human resources.
Top Products and Market Share
Key Offerings
- IMS OneKey: A comprehensive database of healthcare professionals and organizations used for targeting and market research. Competitors include Definitive Healthcare, Veeva Systems. Data on market share specifically for OneKey is not publicly available. It is part of the Technology & Analytics Solutions and the revenue from this is embedded in that revenue segment.
- Clinical Trial Management Systems (CTMS): Platforms that manage clinical trial data, patient enrollment, and regulatory compliance. Competitors include Oracle (Clinical One), Veeva Systems. Data on market share specifically for CTMS is not publicly available. It is part of Research & Development Solutions, and the revenue from this is embedded in that segment's revenue.
- Orchestrated Customer Engagement (OCE): A SaaS platform designed to deliver personalized and coordinated interactions with healthcare professionals. Competitors include Veeva Systems, Salesforce Health Cloud. Data on market share specifically for OCE is not publicly available. It is part of Commercial Solutions, and the revenue from this is embedded in that revenue segment.
Market Dynamics
Industry Overview
The healthcare industry is experiencing growth driven by factors such as aging populations, increased chronic diseases, technological advancements, and regulatory changes. The market for clinical research, healthcare analytics, and commercial services is highly competitive and dynamic.
Positioning
IQVIA is a leading provider of integrated information and technology-enabled healthcare services. Its competitive advantage lies in its scale, comprehensive offerings, and global reach.
Total Addressable Market (TAM)
The global healthcare market is multi-trillion USD. IQVIA is positioned to capture a significant share of the market due to its comprehensive service offerings and global presence.
Upturn SWOT Analysis
Strengths
- Global Scale and Reach
- Comprehensive Service Portfolio
- Extensive Data Assets
- Strong Brand Reputation
- Established Relationships with Pharmaceutical Companies
Weaknesses
- Integration Challenges from Mergers and Acquisitions
- High Debt Levels
- Dependence on the Pharmaceutical Industry
- Complex Organizational Structure
- Pricing pressures due to competition
Opportunities
- Growing Demand for Real-World Evidence
- Expansion into Emerging Markets
- Increased Outsourcing of Clinical Trials
- Adoption of Digital Health Technologies
- Personalized Medicine and Precision Healthcare
Threats
- Regulatory Changes in Healthcare
- Data Privacy Concerns
- Economic Downturns Impacting Healthcare Spending
- Intense Competition
- Cybersecurity Threats
Competitors and Market Share
Key Competitors
- LH
- SYNH
- MEDP
Competitive Landscape
IQVIA's competitive advantage lies in its comprehensive service portfolio and global reach. Competitors specialize in specific areas, such as laboratory services or clinical trial management. IQVIA faces competition from smaller, more agile players.
Major Acquisitions
DeepIntent
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: AI-powered marketing and analytics for healthcare
Advera Health Analytics
- Year: 2021
- Acquisition Price (USD millions): 75
- Strategic Rationale: Added technology and data to their safety reporting systems
Growth Trajectory and Initiatives
Historical Growth: Historical revenue growth has been driven by organic expansion and strategic acquisitions.
Future Projections: Analysts project continued growth in revenue and earnings, driven by demand for healthcare analytics and outsourcing services.
Recent Initiatives: Recent initiatives include expanding its real-world evidence platform, investing in digital health technologies, and pursuing strategic acquisitions.
Summary
IQVIA is a strong player in the healthcare services industry, benefiting from its scale, data assets, and comprehensive offerings. The company's growth is driven by the increasing demand for healthcare analytics and outsourcing services. Potential risks include integration challenges from acquisitions and regulatory changes, requiring ongoing monitoring.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- IQVIA Investor Relations Website
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered as financial advice. Actual financial performance may vary. Market share data is approximate and based on available sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IQVIA Holdings Inc
Exchange NYSE | Headquaters Durham, NC, United States | ||
IPO Launch date 2013-05-09 | CEO & Chairman Mr. Ari Bousbib | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 91000 | Website https://www.iqvia.com |
Full time employees 91000 | Website https://www.iqvia.com | ||
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.